文献速递肥胖与代谢综合征糖尿病

每周一次司美格鲁肽2·4 mg在以东亚人群为主超重或肥胖者中体重管理的有效性与安全性(STEP 7):一项双盲、多中心、随机对照试验

Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2024-02-05

STEP 7研究纳入375例以东亚人群为主的超重或肥胖成人(伴或不伴2型糖尿病),随机2:1接受每周一次司美格鲁肽2·4 mg或安慰剂治疗44周。司美格鲁肽组体重较基线变化-12·1% vs 安慰剂组-3·6%,估计治疗差异-8·5个百分点(95%CI -10·2至-6·8;p<0·0001);减重≥5%者比例85% vs 31%(OR 13·1,95%CI 7·4-23·1;p<0·0001)。结果支持司美格鲁肽2·4 mg用于东亚族裔超重或肥胖者的体重管理。

要点

  • 司美格鲁肽2·4 mg组44周体重变化-12·1%,安慰剂组-3·6%,治疗差异-8·5个百分点(95%CI -10·2至-6·8)。
  • 减重≥5%者比例司美格鲁肽组85%(203/238)vs 安慰剂组31%(36/116),OR 13·1(95%CI 7·4-23·1)。
  • 不良事件发生率司美格鲁肽组93%(231/249)vs 安慰剂组86%(108/126),最常见为胃肠道疾病67% vs 36%。

核心结论

  • 研究结果支持司美格鲁肽2·4 mg用于东亚族裔超重或肥胖(伴或不伴2型糖尿病)者的体重管理。

研究设计与样本

  • 随机3a期、双盲、多中心对照试验(STEP 7),从中国、香港、巴西和韩国的23家医院和试验中心招募受试者。
  • 超重或肥胖成人(伴或不伴2型糖尿病)按2:1随机分配接受每周一次皮下注射司美格鲁肽2·4 mg或安慰剂,共44周,同时进行饮食和体力活动干预。
  • 随机化采用区组大小为6的交互式网络应答系统,按2型糖尿病诊断分层;受试者、研究者和申办方对治疗分配设盲直至数据库锁定后。
  • 主要终点为第44周时平均体重较基线的百分比变化和体重较基线降低至少5%的受试者比例;安全性在所有至少接受一剂研究药物的受试者中评估。
  • 共筛查448人,随机分配375人至司美格鲁肽2·4 mg组(n=249)或安慰剂组(n=126)。

主要发现

  • 第44周体重较基线估计平均百分比变化:司美格鲁肽2·4 mg组-12·1%(SE 0·5)vs 安慰剂组-3·6%(SE 0·7),估计治疗差异-8·5个百分点(95%CI -10·2至-6·8;p<0·0001)。
  • 第44周体重降低≥5%的受试者比例:司美格鲁肽2·4 mg组203/238(85%)vs 安慰剂组36/116(31%),OR 13·1(95%CI 7·4-23·1;p<0·0001)。
  • 不良事件报告率:司美格鲁肽2·4 mg组231/249(93%)vs 安慰剂组108/126(86%);最常见为胃肠道疾病,司美格鲁肽组168/249(67%)vs 安慰剂组45/126(36%)。

临床怎么用

  • 原文结论指出,研究结果支持司美格鲁肽2·4 mg用于东亚族裔超重或肥胖(伴或不伴2型糖尿病)者的体重管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data on the benefits of the once weekly GLP-1 receptor agonist semaglutide 2·4 mg for weight management in people from east Asia are insufficient. The objective of this study was to determine the efficacy and safety of once weekly semaglutide 2·4 mg versus placebo for weight management in a predominantly east Asian adult population. METHODS: This randomised phase 3a, double-blind multicentre controlled trial (STEP 7) recruited participants from 23 hospitals and trial centres in China, Hong Kong, Brazil, and South Korea. Adults with overweight or obesity, with or without type 2 diabetes, were randomly assigned (2:1) to receive a subcutaneous injection of either semaglutide 2·4 mg or placebo once a week for 44 weeks, plus a diet and physical activity intervention. Randomisation was done in blocks of six with an interactive web response system and was stratified by diagnosis of type 2 diabetes. Participants, investigators, and the trial sponsor were masked to treatment allocation until after database lock. Primary endpoints were percentage change in mean bodyweight and proportion of participants having reached a weight reduction of at least 5% of bodyweight from baseline to week 44. Safety was assessed in all participants who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, NCT04251156, and is now complete. FINDINGS: From Dec 8, 2020, to Aug 23, 2022, 448 participants were screened, of whom 375 were randomly assigned to either the semaglutide 2·4 mg group (n=249) or the placebo group (n=126). Estimated mean percentage change in bodyweight from baseline to week 44 was -12·1% (SE 0·5) with semaglutide 2·4 mg versus -3·6% (0·7) with placebo (estimated treatment difference -8·5 percentage points [95% CI -10·2 to -6·8]; p<0·0001). At week 44, the proportion of participants who lost 5% or more of their bodyweight was higher in the semaglutide 2·4 mg group than in the placebo group (203/238 [85%] vs 36/116 [31%]); odds ratio 13·1 (95% CI 7·4-23·1; p<0·0001). Adverse events were reported by 231 (93%) of 249 participants in the semaglutide 2·4 mg group and 108 (86%) of 126 participants in the placebo group, the most common of which were gastrointestinal disorders (168/249, 67% vs 45/126, 36%). INTERPRETATION: The results of this study support the use of semaglutide 2·4 mg for weight management in people of east Asian ethnicity with overweight or obesity and with or without type 2 diabetes. FUNDING: Novo Nordisk. TRANSLATIONS: For the Mandarin, Portuguese and South Korean translations of the abstract see Supplementary Materials section.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Mu Y, Bao X, Eliaschewitz FG, et al. Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2024. PMID: 38330988. doi:10.1016/S2213-8587(23)00388-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。